 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| AEPP CEO Outlines a Clear Path and a Bright Future for an Exciting New Cancer Drug |
|
 Hot Stock to Watch |
Company: Oncolix, Inc. (Pink Sheets: AEPP)
|
Last:
Price: 0.0598
Change (%): - 0.0011 (1.81)
Volume: 156,832 |
 |
Michael T. Redman, Chairman of the Board and CEO of Oncolix, Inc., is Featured in a New Audio Interview at SmallCapVoice.com
AUSTIN, Texas, Sept. 19, 2017 (GLOBE NEWSWIRE) - SmallCapVoice.com, Inc. (SCV) and Oncolix, Inc. (Pink Sheets: AEPP), a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian cancer, today announced that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/9-12-17-smallcapvoice-interview-with-oncolix-inc-aepp.
Michael T. Redman called in to SmallCapVoice.com to go over the business model, management, the ongoing Phase I human clinical trial in ovarian cancer patients and the FDA granting Prolanta Orphan Drug status for the treatment of ovarian cancer in this new interview. Recently the Company consummated a private placement of debt securities, resulting in gross proceeds of 2.0 million dollars. Newbridge Securities Corporation, through LifeTech Capital, acted as lead placement agent for the offering and as financial advisor for the merger.
In the interview Mr. Redman stated, “Our management team is quite diverse because we have experience running companies both big and small and both public and private. A major milestone for 2017 is where we are at in our trials. We have already successfully completed the low dose trials and we are set to begin our mid dose trials. Looking ahead we will be completing a name and ticker symbol change in 2017. We will continue to work with The University Texas MD Anderson Cancer Center to expand our use of Prolanta. In addition, we have a couple of acquisitions in mind to help boost our pipeline. Finally, we are going to strengthen our Board of Directors. I think our shareholders will be very impressed with these additions to our board over the next sixty to ninety days.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
